New combo therapy aims to control stubborn blood disorder
NCT ID NCT07421167
Summary
This study is testing whether adding a new drug called ianalumab to standard platelet-boosting medications is safe and tolerable for adults with primary immune thrombocytopenia (ITP). Researchers want to see if this combination helps improve platelet counts and allows patients to eventually reduce their standard medication. The study will also include a small group of people with a related condition called Evans syndrome.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.